Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
95 studies found for:    peanut allergy
Show Display Options
Download search resultsDownload the search results for:
peanut allergy (95 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Recruiting Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
Condition: Peanut Allergy
Interventions: Biological: AR101 powder provided in capsules & sachets;   Biological: Placebo powder provided in capsules & sachets
2 Recruiting Boiled Peanut Oral Immunotherapy for the Treatment of Peanut Allergy: a Pilot Study
Condition: IgE Mediated Peanut Allergy
Interventions: Other: Desensitisation using boiled peanut;   Other: Desensitisation using boiled peanut (deferred start)
3 Not yet recruiting Placebo-Controlled Study to Investigate ANB020 Activity in Adult Patients With Peanut Allergy
Condition: Peanut Allergy
Interventions: Drug: ANB020;   Drug: Placebo
4 Active, not recruiting Oral Immunotherapy (OIT) for Peanut Allergy
Condition: Peanut Hypersensitivity
Interventions: Drug: Peanut;   Drug: Oat Flour
5 Completed A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy
Conditions: Peanut Hypersensitivity;   Food Hypersensitivity;   Immediate Hypersensitivity
Interventions: Drug: Peanut powder;   Drug: Peanut extract;   Drug: Placebo extract;   Drug: Placebo powder
6 Active, not recruiting Peanut Allergy Oral Immunotherapy Desensitization
Condition: Peanut Allergy
Interventions: Procedure: Peanut protein;   Procedure: Oat flour
7 Withdrawn Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy
Condition: Peanut Allergy
Interventions: Drug: QGE031;   Drug: Placebo
8 Completed Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy
Condition: Peanut Allergy
Interventions: Biological: Viaskin Peanut 50 mcg;   Biological: Viaskin Peanut 100 mcg;   Biological: Viaskin Peanut 250 mcg;   Biological: Viaskin Placebo
9 Recruiting The Role of Filaggrin Mutations and Sensitization Pathways in Allergic Rhinitis and Peanut Allergy
Conditions: Allergic Rhinitis;   Peanut Allergies
10 Completed Epicutaneous Immunotherapy in Peanut Allergy in Children
Condition: Peanut Allergy
Interventions: Biological: Epicutaneous Immunotherapy;   Biological: placebo of peanut
11 Completed Mucosal Immunotherapy for Peanut Allergy
Condition: Food Hypersensitivity
Interventions: Biological: Peanut flour;   Biological: Oat
12 Active, not recruiting Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance
Conditions: Peanut Hypersensitivity;   Food Hypersensitivity;   Food Allergy;   Peanut Allergy
Interventions: Drug: Liquid peanut extract (Peanut SLIT);   Drug: Placebo Glycerin SLIT
13 Completed Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy
Condition: Peanut Hypersensitivity
Interventions: Drug: Peanut Oral Immunotherapy;   Drug: Omalizumab
14 Unknown  Pilot Study to Evaluate the Effect of Ketotifen on the Adverse Events Associated With Peanut Desensitization
Condition: Peanut Allergies in Children
Intervention: Drug: Ketotifen
15 Completed HAL-MPE1 First-in-human
Condition: Peanut Allergy
Interventions: Drug: HAL-MPE1;   Drug: Placebo
16 Completed Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults
Conditions: Food Hypersensitivity;   Hypersensitivity;   Immediate Hypersensitivity;   Peanut Hypersensitivity
Intervention: Biological: E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3
17 Suspended The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy
Condition: Peanut Allergy
Intervention: Drug: Peanut Dissolving Film
18 Completed Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy
Condition: Peanut Allergy
Interventions: Biological: Whole peanut extract;   Biological: Placebo formulation
19 Enrolling by invitation Early Life Origins of the Food Allergy Epidemic
Condition: Allergy to Peanut
Intervention: Procedure: Double-blind placebo-controlled peanut challenge
20 Active, not recruiting
Has Results
Peanut Epicutaneous Phase II Immunotherapy Clinical Trial
Conditions: Peanut Hypersensitivity;   Food Hypersensitivity;   Hypersensitivity;   Hypersensitivity, Immediate
Interventions: Biological: Placebo Viaskin® Patch;   Biological: Low-dose DBV712 Viaskin® Patch;   Biological: High-dose DBV712 Viaskin® Patch

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years